View in EDS

Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor.

Saved in:
Bibliographic Details
Title: Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor.
Authors: Lawless D; Global Health Institute, School of Life Sciences, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland., Allen HL; National Institute for Health Research (NIHR) BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, United Kingdom; MRC Epidemiology Unit, Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom., Thaventhiran JED; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; MRC Toxicology Unit, School of Biological Sciences, University of Cambridge, Cambridge, United Kingdom., Goddard S; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom., Burren OS; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom., Robson E; Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom., Peckham D; Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom; Leeds Institute of Medical Research at St James's University Hospital, University of Leeds, Leeds, United Kingdom., Smith KGC; National Institute for Health Research (NIHR) BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, United Kingdom., Savic S; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, United Kingdom; Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James's University Hospital, Leeds, United Kingdom. Electronic address: s.savic@leeds.ac.uk.
Corporate Authors: NIHR BioResource–Rare Diseases Consortium; National Institute for Health Research (NIHR) BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Source: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2023 Jul; Vol. 152 (1), pp. 257-265. Date of Electronic Publication: 2023 Feb 23.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825 (Electronic) Linking ISSN: 00916749 NLM ISO Abbreviation: J Allergy Clin Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6825
DOI:10.1016/j.jaci.2023.01.035